ATTN: We are committed to keeping our patients informed regarding the recent cybersecurity incident involving McKesson. At this time, we are continuing to monitor the situation closely and are working to obtain the most current information available. We will provide updates as we receive additional information from McKesson and learn more about any potential impact. Thank you for your patience and trust as we navigate this situation together. CLICK HERE for more information.

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 25007
Patient Portal Cancer Resources

Listen to our podcast

RSS Feed

USO 25007

MK1022-016: An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

• HR+/HER2- BC LA/MBC
• Centrally-confirmed ER, PR, HER2 and HER3 results from
metastatic site on/after the most recent line of therapy
• PD on 1L CDK4/6i + ET for MBC OR Relapse while on or within 24
months from last dose of adjuvant CDK4/6i + ET
• Pts who received single agent CDK 4/6i or a 2L of ET based tx for
MBC are excluded
• Measurable disease or bone only with lytic/mixed lytic lesions
• Candidate for at least 1 TPC option
• Known germline BRCA mutations are excluded
• Prior chemotherapy for advanced setting is excluded
• Prior tx with an anti-HER3 ab and/or ADC with topo I inhibitor are
excluded.

For more information on this study CLICK HERE .

Available at:

Virginia Oncology Associates